STOCKSCREENR

VRTX

NASDAQ

Vertex Pharmaceuticals Incorporated

$427.38+4.14(+0.98%)Mkt Cap: $108.71B

Key Stats

Market Cap

$108.71B

P/E Ratio

27.90

EPS

$15.32

Dividend Yield

0.00%

52-Week Range

$362.50 — $509.00

Volume

1.12M

Avg Volume

1.36M

Beta

0.37

Price Alerts for VRTX

Get alerted when VRTX hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

27.90

Forward P/E

22.12

PEG Ratio

-9.81

P/S (TTM)

8.94

P/B (TTM)

5.76

P/FCF

87.84

EV/EBITDA

71.53x

EV/Sales

—

Financial Health

ROE (TTM)

0.23%

ROA (TTM)

0.15%

ROIC

0.06%

Gross Margin

0.86%

Operating Margin

0.35%

Net Margin

0.35%

Debt/Equity

0.21

Current Ratio

2.90

Growth

EPS Growth (YoY)

+0.05%

Revenue Growth (YoY)

+0.12%

EPS Growth (3Y)

+2.46%

EPS Growth (5Y)

+1.53%

Sales Growth (3Y)

+0.10%

Sales Growth (5Y)

+0.14%

EPS Est (This Year)

$19.32

EPS Est (Next Year)

$22.16

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

0.00%

Frequency

—

Ex-Dividend Date

—

Cash/Share

$26.04

Analyst Consensus

2.0

Buy

1 = Strong Buy, 5 = Strong Sell

Price Target Range

$441.00$558.00$607.00
LowMedianHigh

Consensus Target: $549.31(28.5% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

254.00M

Float

253.20M

Free Float %

99.68%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

1991-07-24

Employees

6100

CEO

Reshma Kewalramani

Index Membership

S&P 500

Website

https://www.vrtx.com

Vertex Pharmaceuticals Incorporated (VRTX) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $108.71B, a P/E ratio of 27.90, VRTX is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare VRTX against other stocks using dozens of fundamental and technical filters.

Similar Stocks

ARGX

argenx SE

$781.72

+0.73%

$48.38B

0QW0.L

argenx SE

$661.80

+1.77%

$25.13B

RVMD

Revolution Medicines, Inc.

$144.12

+2.54%

$30.08B

REGN

Regeneron Pharmaceuticals, Inc.

$707.06

+3.02%

$73.47B

ALNY

Alnylam Pharmaceuticals, Inc.

$309.49

+2.76%

$41.29B

INSM

Insmed Incorporated

$136.33

+0.96%

$29.43B

Frequently Asked Questions

What is Vertex Pharmaceuticals Incorporated's P/E ratio?

Vertex Pharmaceuticals Incorporated (VRTX) has a trailing twelve-month (TTM) P/E ratio of 27.90. This is near the market average range. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Vertex Pharmaceuticals Incorporated pay a dividend?

No, Vertex Pharmaceuticals Incorporated (VRTX) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Vertex Pharmaceuticals Incorporated's market cap?

Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of $108.71 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.

What do analysts think about VRTX?

Wall Street analysts have a consensus "Buy" rating on Vertex Pharmaceuticals Incorporated (VRTX) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $549.31 implies 28.5% upside from the current price.